Marked effect of liver and kidney function on the pharmacokinetics of selegiline

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 1, 2005, Pages 54-62

  Anttila, Markku ^a,b   Sotaniemi, Eero A ^a   Pelkonen, Olavi ^a   Rautio, Arja ^a  

^a Turku Dept Pharmacol Toxicol U ^*  (Finland)

^b Finland   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETAXOLOL; CAPTOPRIL; DIGOXIN; DILTIAZEM; DIPYRIDAMOLE; DRUG METABOLITE; ENALAPRIL; FUROSEMIDE; GLIBENCLAMIDE; GLIPIZIDE; GLYCEROL NITRATE; GUAR GUM; IBUPROFEN; INSULIN; ISOSORBIDE 5 NITRATE; LISINOPRIL; LIVER ENZYME; METFORMIN; METOPROLOL; NIFEDIPINE; PREDNISOLONE; PROPRANOLOL; SELEGILINE; SOTALOL; VERAPAMIL; WARFARIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER DISEASE; LIVER FUNCTION; MALE; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE;

AGED; AREA UNDER CURVE; BIOTRANSFORMATION; CASE-CONTROL STUDIES; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; SELEGILINE;

EID: 11344267293     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.09.004     Document Type: Article

References (24)

1. J. Knoll (-)Deprenyl (selegiline): past, present and future Neurobiology (Bp) 8 2000 179 199
2. J. Romrell, H.H. Fernandez, M.S. Okun Rationale for current therapies in Parkinson's disease Expert Opin Pharmacother 4 2003 1747 1761
3. F. Stocchi, C.W. Olanow Neuroprotection in Parkinson's disease: clinical trials Ann Neurol 53 Suppl 3 2003 S87 99
4. E.H. Heinonen, M.I. Anttila, R. Lammintausta Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites Clin Pharmacol Ther 56 1994 742 749
5. E.H. Heinonen, M. Anttila, H. Karnani, R. Lammintausta Pharmacokinetics of selegiline after oral dosing [abstract] Mov Disord 9 1994 57
6. T. Yoshida, Y. Yamada, T. Yamamoto, Y. Kuroiwa Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitor potency Xenobiotica 16 1986 129 136
7. H.S. Shin Metabolism of selegiline in humans Identification, excretion, and stereochemistry of urine metabolites Drug Metab Dispos 25 1997 657 662
8. P. Taavitsainen, M. Anttila, L. Nyman, H. Karnani, J.S. Salonen, O. Pelkonen Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes Pharmacol Toxicol 86 2000 215 221
9. M. Hidestrand, M. Oscarson, J.S. Salonen, L. Nyman, O. Pelkonen, M. Turpeinen CYP2B6 and CYP2C19 are the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes Drug Metab Dispos 29 2001 1480 1484
10. J.S. Salonen, L. Nyman, A.R. Boobis, R.J. Edwards, P. Watts, B.G. Lake Comparative studies on the CYP-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems Drug Metab Dispos 31 2003 1093 1102
11. E.H. Heinonen, V. Myllylä, K. Sotaniemi, R. Lammintausta, J.S. Salonen, M. Anttila Pharmacokinetics and metabolism of selegiline Acta Neurol Scand 126 1989 93 99
12. H. Scheinin, M. Anttila, M.-L. Dahl, H. Karnani, L. Nyman, P. Taavitsainen CYP2D6 polymorphism is not crucial for the disposition of selegiline Clin Pharmacol Ther 64 1998 402 411
13. M. Turpeinen, R. Nieminen, T. Juntunen, P. Taavitsainen, H. Raunio, O. Pelkonen Selective inhibition of CYP2B6 catalyzed bupropion hydroxylation in human liver microsomes in vitro Drug Metab Dispos 32 2004 626 631
14. R.J. Edwards, R.J. Price, P.S. Watts, A.B. Renwick, J.M. Tredger, A.R. Boobis Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices Drug Metab Dispos 31 2003 282 288
15. A. Madan, R.A. Graham, K.M. Carroll, D.R. Mudra, L.A. Burton, L.A. Krueger Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes Drug Metab Dispos 31 2003 421 431
16. H. Martin, J.P. Sarsat, I. de Waziers, C. Housset, P. Balladur, P. Beaune Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices Pharm Res 20 2003 557 568
17. K. Laine, M. Anttila, L. Nyman, A. Wahlberg, L. Bertilsson CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline Eur J Clin Pharmacol 57 2001 137 142
18. K.T. Kivistö, J.S. Wang, J.T. Backman, L. Nyman, P. Taavitsainen, M. Anttila Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole Eur J Clin Pharmacol 57 2001 37 42
19. V. Rodighiero Effects of liver disease on pharmacokinetics An update Clin Pharmacokinet 37 1999 399 431
20. T.D. Nolin, R.F. Frye, G.R. Matzke Hepatic drug metabolism and transport in patients with kidney disease Am J Kidney Dis 42 2003 906 925
21. T.D. Nolin, M.R. Gastonguay, R.R. Bies, G.R. Matzke, R.F. Frye Impaired 6-hydroxy-chlorzoxazone elimination in patients with kidney disease: implication for cytochrome P450 2E1 pharmacogenetic studies Clin Pharmacol Ther 74 2003 555 568
22. A.W. Dreisbach, S. Japa, A.B. Gebrekal, S.E. Mowry, J.J.L. Lertora, B.L. Kamath Cytochrome P4502C9 activity in end-stage renal disease Clin Pharmacol Ther 73 2003 475 477
23. T.C. Dowling, A.E. Briglia, J.C. Fink, D.S. Hanes, P.D. Light, L. Stackiewicz Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease Clin Pharmacol Ther 73 2003 427 434
24. T. Kraemer, H.H. Maurer Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives Ther Drug Monit 24 2002 277 289